Company intelligence / Profile preview
iDD Biotech
Lyon, Franceidd-biotech.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Other
01
Overview
iDD Biotech has a pipeline consisting of four pre-clinical therapeutic monoclonal antibodies and four active drug discovery programs targeting cancer, infectious, autoimmune, and CNS diseases. No clinical results have been reported publicly yet.
- Therapeutic areas
- Infectious DiseasesOncologyImmunologyNeurology
- Modalities
- Monoclonal antibodyAntibody-drug conjugateMultivalent antibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Research institutes (undisclosed)Biotechnology companies (undisclosed)Medium size and large pharmaceutical companies (undisclosed)
Beyond the preview
Go deeper on iDD Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iDD Biotech.